Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

MERCK & CO., INC.

(MRK)
  Report
Delayed Nyse  -  04:04 2022-09-30 pm EDT
86.12 USD   -0.60%
09/29U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
BU
09/29Global markets live: Berkshire Hathaway, Tesla, Twitter, Amazon, Starbucks...
MS
09/29Momentum Picks: 5 stocks for the fall
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca and Merck - FDA Accepts Submission of Supplemental New Drug Application for LYNPARZA (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone for Patients With Metastatic Castration

08/17/2022 | 08:43am EDT

RAHWAY, N.J. - AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that a supplemental New Drug Application (sNDA) for LYNPARZA in combination with abiraterone and prednisone or prednisolone has been accepted and granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC). The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date in the fourth quarter of 2022.

In the U.S., prostate cancer is the second most common cancer in male patients. Approximately 10-20% of male patients with advanced prostate cancer are estimated to develop castration resistant prostate cancer (CRPC) within five years, and at least 84% of these men may develop metastases at the time of CRPC diagnosis. Patients with advanced prostate cancer have a particularly poor prognosis, and the five-year survival rate remains low.

Susan Galbraith, executive vice president, oncology R&D, AstraZeneca, said, 'There remains a critical unmet need among patients diagnosed with mCRPC, where the prognosis remains poor, and treatment options are limited. Today's news is another step towards bringing forward a new, much-needed treatment option in this setting. If approved, LYNPARZA with abiraterone will become the first combination of a PARP inhibitor and a new hormonal agent for patients with this disease.'

Dr. Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, said, 'Merck is committed to developing new treatment options for patients with mCRPC, a complex disease that urgently needs more therapies. We look forward to working with the FDA towards the goal of bringing a new option to patients with mCRPC with or without homologous recombination repair gene mutations.'

The sNDA was based on results from the Phase 3 PROpel trial, which were presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium and later published in NEJMEvidence.

In PROpel, LYNPARZA in combination with abiraterone and prednisone or prednisolone reduced the risk of disease progression or death by 34% (HR=0.66 [95% CI, 0.54-0.81]; p

(C) 2022 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC 0.11% 9944 Delayed Quote.14.59%
MERCK & CO., INC. -0.60% 86.12 Delayed Quote.12.37%
All news about MERCK & CO., INC.
09/29U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Di..
BU
09/29Global markets live: Berkshire Hathaway, Tesla, Twitter, Amazon, Sta..
MS
09/29Momentum Picks: 5 stocks for the fall
MS
09/29Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
BU
09/29Merck & Co. Awards Sinopharm Chinese Distribution Rights For COVID-19 Drug
MT
09/28Merck's KEYTRUDA (pembrolizumab) Receives Four New Approvals in Japan, Including in Hig..
AQ
09/27Merck & Co.'s Keytruda Wins Four New Approvals in Japan for Cancer Indications
MT
09/27Merck Division Merck Animal Health Closes Minority Investment in LeeO Precision Farming
MT
09/27TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoin..
AQ
09/27ETF Preview: ETFs, Futures Bounce Pre-Bell After Recession Fears Prompted Se..
MT
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2022 58 623 M - -
Net income 2022 15 200 M - -
Net Debt 2022 18 009 M - -
P/E ratio 2022 13,9x
Yield 2022 3,29%
Capitalization 218 B 218 B -
EV / Sales 2022 4,03x
EV / Sales 2023 3,99x
Nbr of Employees 67 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 86,12 $
Average target price 100,00 $
Spread / Average Target 16,1%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Dave Williams EVP, Chief Information & Digital Officer
Lisa LeCointe-Cephas Chief Ethics & Compliance Officer, SVP
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.12.37%218 166
JOHNSON & JOHNSON-4.51%429 503
ELI LILLY AND COMPANY19.47%307 239
ROCHE HOLDING AG-14.68%271 055
PFIZER, INC.-25.89%245 597
ABBVIE INC.-0.88%237 296